Medicenna Therapeutics Corp.
BioTech/Drugs - Toronto, ON, CA
Medicenna Therapeutics Corp. Employees
Medicenna Therapeutics Corp. Senior Management
Medicenna Therapeutics Corp. Details
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna's early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically "cold" tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.
Medicenna Therapeutics Corp. Technologies
Email Providers
Gmail
Domain Name Services
EasyDNS
Other
Google Apps
Hosting
Google Cloud Hosting
Search Marketing
Adobe Marketing Cloud
CSS and JavaScript Libraries
Bootstrap Framework